ApoE testing
ApoE ε4 is a risk variant used in antibody-safety counselling. It does not diagnose Alzheimer’s disease.
Overview
US labels for amyloid antibodies discuss ApoE ε4 and ARIA risk. Testing needs consent and counselling, not a casual consumer kit used as a diagnosis.
- Copied DNA with a repeat run
- MLH1, PMS2, MSH2, MSH6: one lost
- IHC, then PCR or NGS
- Immunotherapy, and Lynch screening
How it works
Genotyping APOE alleles, especially ε4, to inform ARIA risk discussions.
Latest papers
topQuery for this technology: (TITLE:"ApoE testing" OR ABSTRACT:"ApoE testing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ApoE testing, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyAnti-amyloid antibodies
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyEisai
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisMild cognitive impairment
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- PairingLecanemab with MRI monitoring
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.